People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Other Health Care, Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Direct Flow Medical, Inc. | — | Other Health Care | Series C | $170.5M | $619.6M | 2009 |
| Octave Bioscience Inc | — | Biotech | Series B | $105.8M | $169.5M | 2020 |
| Auxogyn Inc | — | Other Health Care | Series B | $73.1M | $327.3M | 2015 |
| Carbylan Therapeutics, Inc. | — | Other Health Care | Series A | $15.0M | $80.7M | 2012 |
Mark Weeks at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Weeks on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Beth Seidenberg | 1 | 15 |
| Brook Byers | 1 | 13 |
| Fred Cohen | 1 | 12 |
| PAUL LAVIOLETTE | 1 | 12 |
| Albert Cha | 1 | 9 |
| Simeon George | 1 | 8 |
| Jeani Delagardelle | 1 | 8 |
| Michael DeVries | 1 | 8 |
| Greg Garfield | 1 | 8 |
| J. Daniel Cole | 1 | 7 |
| Chris Ehrlich | 1 | 6 |
| Andrea Jackson | 1 | 6 |
| Thomas Hawes | 1 | 6 |
| Mark Gudiksen | 1 | 5 |
| Lee Wrubel | 1 | 5 |
| Guy Nohra | 1 | 5 |
| Nilesh Kumar | 1 | 4 |
| George Scangos | 1 | 4 |
| William Hagstrom | 1 | 4 |
| Michael Pellini | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.